Personal injury lawyers announce that Takeda Pharmaceutical and Affymax are recalling all lots of Omontys after the Food and Drug Administration received 19 reports of anaphylaxis, a severe allergic reaction. According to the FDA, three of the cases have resulted in patient deaths. Patients have required prompt medical attention or hospitalization on other instances.

Omontys, also known as peginesatide, treats anemia in patients undergoing kidney dialysis. Affymax and Takeda said that roughly 25,000 patients have been treated with Omontys since its approval last March. Prior to the approval of Omontys, Amgen’s Epogen had been the only drug used to treat anemia in dialysis clinics since 1989.

Personal Injury Lawyers Tell Patients What to Consider If They Have Taken Omontys

According to Takeda and Affymax, adverse reactions to Omontys usually occurred within 30 minutes of a patient receiving their first dose by intravenous administration. So far, there have not been any reports of issues resulting from subsequent doses. However, the FDA and the drug’s manufacturers recommend that all patients discontinue use of Omontys; even those who have already taken more than one dose.

New Jersey and Philadelphia Personal Injury Lawyers

The Philadelphia personal injury lawyers at Messa & Associates are experienced at handling pharmaceutical cases in which a defective drug product has caused injury or death. Our extremely skilled team of personal injury lawyers and medical experts is dedicated to ensuring you receive proper compensation for your personal injuries. If you have suffered an injury as a result of a pharmaceutical drug including Omontys, drug product, another defective product, or any other type of personal injury, contact the personal injury lawyers of Messa & Associates for a free consultation. Call toll free at 1-877-MessaLaw, or submit a free online inquiry.